May be useful in the assessment of acute or chronic elemental or inorganic mercury exposure and/or in monitoring chelation therapy. For the assessment of acute exposure, Mercury, Whole Blood (0099305) is preferred.
Quantitative Inductively Coupled Plasma-Mass Spectrometry
Diet, medication, and nutritional supplements may introduce interfering substances. Patients should be encouraged to discontinue nutritional supplements, vitamins, minerals, and non-essential over-the-counter medications (upon the advice of their physician), and avoid shellfish and seafood for 48 to 72 hours. High concentrations of iodine may interfere with elemental testing. Collection of urine specimens from patients receiving iodinated or gadolinium-based contrast media should be avoided for a minimum of 72 hours post-exposure. Collection from patients with impaired kidney function should be avoided for a minimum of 14 days post-contrast media exposure.
Transfer an 8 mL aliquot from a well-mixed collection to ARUP Trace Element-Free Transport Tubes (ARUP supply #43116), available online through eSupply using ARUP Connect or contact ARUP Client Services at (800) 522-2787. (Min: 1 mL).
Refrigerated. Also acceptable: Room temperature or frozen.
Urine collected within 72 hours after administration of iodinated or gadolinium-based contrast media. Acid preserved urine. Specimens contaminated with blood or fecal material. Specimens transported in non-trace element free transport tube (with the exception of the original device).
Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 1 year
Effective November 12,2018
|Mercury, Urine - per volume||0.0-5.0 µg/L|
|Mercury, Urine - ratio to CRT||0.0-20.0 µg/gCRT|
Urinary mercury levels predominantly reflect acute or chronic elemental or inorganic mercury exposure. Urine concentrations in unexposed individuals are typically less than 10 µg/L. 24-hour urine concentrations of 30 to 100 µg/L may be associated with subclinical neuropsychiatric symptoms and tremors. Concentrations greater than 100 µg/L can be associated with overt neuropsychiatric disturbances and tremors. Urine mercury levels may be useful in monitoring chelation therapy.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|0020207||Creatinine, Urine - per volume||2161-8|
|0025052||Mercury, Urine - per volume||5689-5|
|0025054||Mercury, Urine - ratio to CRT||13465-0|
- Urine Hg
- Urine mercury concentration